Mobic (Meloxicam) Is NOT a Muscle Relaxant for Back Pain
Mobic (meloxicam) is an NSAID, not a muscle relaxant, and should be used as first-line therapy for acute low back pain—but if muscle relaxation is specifically needed, a true skeletal muscle relaxant like tizanidine should be added. 1, 2, 3
Understanding the Medication Class
- Meloxicam is a COX-2 preferential NSAID that works by inhibiting prostaglandin synthesis to reduce inflammation and pain—it has no direct muscle relaxant properties. 4, 5
- The FDA has approved meloxicam specifically for osteoarthritis and rheumatoid arthritis, not as a muscle relaxant. 4
- Meloxicam exhibits anti-inflammatory, analgesic, and antipyretic activities through cyclooxygenase inhibition, not through muscle relaxation mechanisms. 4
Evidence-Based Treatment Algorithm for Acute Low Back Pain
First-Line Pharmacologic Therapy
- NSAIDs (including meloxicam) or acetaminophen should be the initial pharmacologic approach for acute low back pain. 1, 2
- Meloxicam 7.5-15 mg daily has demonstrated moderate superiority over placebo for short-term pain reduction (mean difference -7.29 on 0-100 VAS scale) and disability improvement. 6, 7
- The typical dosing regimen involves meloxicam 15 mg/day intramuscularly for 3-5 days, then switching to oral 7.5-15 mg for up to 14 days. 8, 9
Adding True Muscle Relaxants When Needed
- If pain persists after first-line NSAIDs, adding a skeletal muscle relaxant like tizanidine is the evidence-based next step. 1, 3
- Skeletal muscle relaxants have good evidence for effectiveness in acute low back pain (not chronic), providing moderate short-term pain relief with a relative risk of 0.80 for pain reduction at 2-4 days. 1, 10
- Tizanidine is the preferred muscle relaxant based on superior safety profile compared to baclofen, with lower rates of injury, delirium, falls, and opioid overdose in older adults. 3
Specific Muscle Relaxant Recommendations (When Indicated)
Tizanidine Dosing
- Start at 2 mg up to three times daily, then titrate slowly based on response and tolerability. 3
- Monitor for muscle weakness, urinary retention, cognitive changes, sedation, and orthostatic hypotension. 3
- Check liver function tests periodically, as tizanidine can cause reversible hepatotoxicity. 3
Duration of Therapy
- Muscle relaxant therapy should be time-limited; extended courses are reserved only for patients showing continued benefit without major adverse events. 2, 3
- Most muscle relaxant trials were ≤2 weeks duration, with insufficient evidence for long-term efficacy in chronic low back pain. 3, 10
Safety Considerations for Meloxicam
- All NSAIDs, including meloxicam, carry gastrointestinal, cardiovascular, and renal risks—not the sedation and CNS effects typical of muscle relaxants. 6, 4
- Meloxicam has demonstrated lower gastrointestinal toxicity compared to non-selective NSAIDs due to its COX-2 preferential activity. 5, 11
- Adverse events with meloxicam occurred at rates similar to traditional NSAIDs (4.6% in observational studies), including peripheral edema and hypertension. 9, 11
Clinical Efficacy Data
- Complete pain relief was achieved in 75.2% of acute low back pain patients treated with meloxicam 15 mg/day over a mean of 8.6 days. 9
- Younger patients (<65 years), those with first episodes of back pain, and those with previous good NSAID response had better outcomes. 9
- Severe baseline pain (≥7/10), pain at rest, nocturnal pain, and sciatica were associated with poorer treatment outcomes requiring integrated therapy. 9
Common Pitfall to Avoid
The critical error is assuming meloxicam provides muscle relaxation—it does not. If muscle spasm is a significant component of the back pain, you must add a true skeletal muscle relaxant (tizanidine, cyclobenzaprine, or methocarbamol) to the NSAID regimen rather than relying on meloxicam alone. 1, 3, 10